Tryp Therapeutics Inc.

As of November 30, 2023, Tryp Therapeutics Inc. has 96.42M shares outstanding.

These figures are as of November 30, 2023.

As of November 30, 2023, Tryp Therapeutics Inc. maintains a current ratio of 0.31, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -102.46, indicating conservative leverage, while an interest coverage ratio of -69.67 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended November 30, 2023. Return on assets (ROA) is negative at -265.27, reflecting losses generated across the asset base.

These figures cover the twelve months ended November 30, 2023. Free cash flow yield is negative at -74.92: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -99.84, meaning Tryp Therapeutics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of November 30, 2023, Tryp Therapeutics Inc. has an Altman Z-Score of -22.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.